Related Experiment Videos
Thrombosis prophylaxis after treatment during pregnancy
G Daskalakis1, A Antsaklis, I Papageorgiou
1First Department of Obstetrics and Gynaecology, Athens University Medical School, Alexandra Maternity Hospital, Greece.
Summary
Deep vein thrombosis (DVT) in pregnancy is manageable with heparin. Low molecular weight heparin (LMWH) is a safe and effective treatment option for pregnant women, offering advantages over standard heparin.
Area of Science:
- Obstetrics and Gynecology
- Hematology
- Pharmacology
Background:
- Deep vein thrombosis (DVT) is a significant risk during pregnancy and postpartum due to physiological changes in coagulation.
- Pregnancy-related DVT requires careful management to ensure maternal and fetal well-being.
Purpose of the Study:
- To present cases of DVT during pregnancy and evaluate treatment outcomes.
- To assess the safety and efficacy of heparin and low molecular weight heparin (LMWH) in managing pregnancy-associated DVT.
Main Methods:
- Retrospective review of eighteen pregnant patients diagnosed with DVT.
- Treatment initiated with adjusted-dose subcutaneous heparin, followed by daily subcutaneous LMWH until one month postpartum.
Main Results:
- All patients completed treatment, with uneventful labor in most cases.
- One case of missed abortion occurred in the first trimester.
- No adverse side-effects were reported during heparin or LMWH treatment.
Conclusions:
- Low molecular weight heparin (LMWH) is a preferred treatment for thromboembolic events in pregnant women.
- LMWH offers advantages over standard heparin for managing DVT during pregnancy and postpartum.